REG-Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
Oculis reported Q3 2026 results with $252.0 million in cash and short-term investments, providing runway into 2H 2029, and no revenue as a clinical-stage biotech. PREDICT-1 randomization is complete with 176 patients enrolled; topline data for Licaminlimab in TNFR1-mediated dry eye disease are expected around year-end 2026, and IND clearance for Privosegtor in acute MS relapses is expected in Q4 2026. Q3 R&D expense rose to $18.5 million (from $17.6 million) and G&A to $10.6 million (from $8.0 million); nine-month net loss narrowed to $71.7 million from $89.7 million, helped by warrant fair-value gains and FX.
Key figures
- Cash runway
- into 2H 2029
- Q3 ga expense
- $10.6 million
- Q3 rnd expense
- $18.5 million
- Nine month net loss
- $71.7 million
- Predict1 enrollment
- 176 patients randomized
- Cash and investments
- $252.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.